HER2/ErbB2 Monoclonal antibody

HER2/ErbB2 Monoclonal Antibody for IF, FC, IHC, ELISA

Host / Isotype

Mouse / IgG2b









Cat no : 60311-1-Ig


CD340, ERBB2, HER 2, HER 2/neu, HER2, MLN 19, MLN19, NEU, NGL, p185, p185erbB2, Proto oncogene c ErbB 2, Proto oncogene Neu, TKR1

Tested Applications

Positive IHC detected inhuman breast cancer tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
Positive IF detected inhuman breast cancer tissue
Positive FC detected inSK-BR-3 cells

Recommended dilution

Immunohistochemistry (IHC)IHC : 1:800-1:3200
Immunofluorescence (IF)IF : 1:50-1:500
Flow Cytometry (FC)FC : 0.40 ug per 10^6 cells in a 100 µl suspension
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

60311-1-Ig targets HER2/ErbB2 in IF, FC, IHC, ELISA applications and shows reactivity with human samples.

Tested Reactivity human
Cited Reactivityhuman
Host / Isotype Mouse / IgG2b
Class Monoclonal
Type Antibody
Immunogen HER2/ErbB2 fusion protein Ag16463
Full Name v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)
Calculated Molecular Weight 1255 aa, 138 kDa
GenBank Accession NumberBC156755
Gene Symbol ERBB2
Gene ID (NCBI) 2064
Conjugate Unconjugated
Form Liquid
Purification MethodProtein A purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Background Information

HER2, also known as ErbB2 and Neu, is a 185-kDa transmembrane glycoprotein that is a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. It has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Amplification and/or overexpression of HER2 have been reported in numerous cancers, including breast and ovarian tumors. HER2 is a therapeutic target for the treatment of breast cancer and other carcinomas.


Product Specific Protocols
IHC protocol for HER2/ErbB2 antibody 60311-1-IgDownload protocol
IF protocol for HER2/ErbB2 antibody 60311-1-IgDownload protocol
FC protocol for HER2/ErbB2 antibody 60311-1-IgDownload protocol
Standard Protocols
Click here to view our Standard Protocols



J Cancer

InvivoPen: A novel plasma source for in vivo cancer treatment.

Authors - Xin Zhou

Mol Med Rep

HPK1 positive expression associated with longer overall survival in patients with estrogen receptor-positive invasive ductal carcinoma‑not otherwise specified.

Authors - Jiaojiao Wang

Oncol Lett

Circulating HER-2 mRNA in the peripheral blood as a potential diagnostic and prognostic biomarker in females with breast cancer.

Authors - Yanlin Wu

Mol Cancer

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer

Authors - Fei Xing